Elizabeth Smyth, MD, FRCP - When They Need More Than Trastuzumab: Deciding on What’s Next for Patients With HER2+ Gastric Cancer
Update: 2024-09-23
Description
Visit https://www.peervoice.com/SKB860 to view the entire programme with slides. After completing “Elizabeth Smyth, MD, FRCP - When They Need More Than Trastuzumab: Deciding on What’s Next for Patients With HER2+ Gastric Cancer”, participants will be able to: Discuss the need for early identification of relapse or disease progression in patients with HER2+ gastric/gastroesophageal junction (GEJ) cancer who are receiving HER2-targeted therapy; Identify how approved and investigational antibody-drug conjugate (ADC) therapies for HER2+ gastric/GEJ cancer are differentiated, based on clinical data and line of therapy; Explain the rationale for retesting HER2-positivity in patients with gastric/GEJ cancer who have progressed on HER2-targeted therapy; and Propose evidence-based treatment plans for patients with HER2+ gastric/GEJ cancer who have progressed on HER2-targeted therapy, based on patient and disease characteristics.
Comments
Top Podcasts
The Best New Comedy Podcast Right Now – June 2024The Best News Podcast Right Now – June 2024The Best New Business Podcast Right Now – June 2024The Best New Sports Podcast Right Now – June 2024The Best New True Crime Podcast Right Now – June 2024The Best New Joe Rogan Experience Podcast Right Now – June 20The Best New Dan Bongino Show Podcast Right Now – June 20The Best New Mark Levin Podcast – June 2024
In Channel